$1.51 Billion is the total value of Frazier Life Sciences Management, L.P.'s 52 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $204,464,387 | +81.3% | 6,470,392 | +48.4% | 13.58% | +101.6% |
| HILLEVAX INC | $131,560,798 | -21.8% | 9,781,472 | 0.0% | 8.74% | -13.0% | ||
| KRYS | Sell | KRYSTAL BIOTECH INC | $114,661,360 | -1.4% | 988,460 | -0.2% | 7.62% | +9.7% |
| Buy | NEWAMSTERDAM PHARMA COMPANYordinary shares | $112,218,271 | -13.2% | 12,131,705 | +11.6% | 7.45% | -3.5% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $104,833,223 | -27.6% | 10,109,279 | 0.0% | 6.96% | -19.5% | |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $71,883,275 | +110.1% | 2,725,949 | +37.1% | 4.77% | +133.7% |
| PCVX | VAXCYTE INC | $59,361,367 | +2.1% | 1,164,405 | 0.0% | 3.94% | +13.5% | |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $54,362,144 | +52.1% | 2,371,304 | +9.4% | 3.61% | +69.2% |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $49,133,889 | -21.1% | 3,014,349 | +2.4% | 3.26% | -12.2% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $47,284,548 | +85.5% | 1,589,931 | +12.4% | 3.14% | +106.2% |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $46,113,272 | -44.3% | 8,684,232 | 0.0% | 3.06% | -38.0% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $34,186,918 | +11.4% | 2,985,757 | 0.0% | 2.27% | +23.9% | |
| TARS | TARSUS PHARMACEUTICALS INC | $31,764,355 | -1.7% | 1,787,527 | 0.0% | 2.11% | +9.4% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $31,190,212 | +7.0% | 3,238,859 | 0.0% | 2.07% | +19.0% | |
| DISC MEDICINE INC | $30,771,900 | +5.8% | 655,000 | 0.0% | 2.04% | +17.7% | ||
| RCKT | New | ROCKET PHARMACEUTICALS INC | $28,747,736 | – | 1,403,013 | +100.0% | 1.91% | – |
| RVMD | Buy | REVOLUTION MEDICINES INC | $27,609,554 | +20.8% | 997,455 | +16.7% | 1.83% | +34.4% |
| APLS | New | APELLIS PHARMACEUTICALS INC | $23,358,196 | – | 614,043 | +100.0% | 1.55% | – |
| New | AN2 THERAPEUTICS INC | $22,333,335 | – | 1,388,889 | +100.0% | 1.48% | – | |
| MRUS | MERUS N V | $17,601,975 | -10.4% | 746,479 | 0.0% | 1.17% | -0.4% | |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $16,350,045 | -4.2% | 1,204,867 | +21.1% | 1.09% | +6.6% |
| ANAB | ANAPTYSBIO INC | $16,158,612 | -11.7% | 899,700 | 0.0% | 1.07% | -1.8% | |
| SVRA | New | SAVARA INC | $15,120,000 | – | 4,000,000 | +100.0% | 1.00% | – |
| TRVI | TREVI THERAPEUTICS INC | $15,000,776 | -8.8% | 6,881,090 | 0.0% | 1.00% | +1.4% | |
| COGT | COGENT BIOSCIENCES INC | $14,638,484 | -17.7% | 1,501,383 | 0.0% | 0.97% | -8.5% | |
| Buy | ENLIVEN THERAPEUTICS INC | $14,349,598 | -15.4% | 1,050,483 | +26.4% | 0.95% | -5.9% | |
| TYRA BIOSCIENCES INC | $14,155,739 | -19.1% | 1,028,013 | 0.0% | 0.94% | -10.1% | ||
| New | SOLENO THERAPEUTICS INC | $13,720,291 | – | 464,937 | +100.0% | 0.91% | – | |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $13,147,893 | -36.0% | 630,897 | -26.4% | 0.87% | -28.8% |
| ORIC | ORIC PHARMACEUTICALS INC | $12,964,273 | -22.0% | 2,142,855 | 0.0% | 0.86% | -13.3% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $8,730,177 | -2.1% | 3,746,857 | 0.0% | 0.58% | +8.8% | |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $8,712,000 | -88.8% | 600,000 | -83.8% | 0.58% | -87.5% |
| SLN | SILENCE THERAPEUTICS PLCads | $8,661,931 | +78.7% | 881,173 | 0.0% | 0.58% | +99.0% | |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $8,579,190 | -31.3% | 393,000 | 0.0% | 0.57% | -23.6% | |
| New | APOGEE THERAPEUTICS INC | $8,520,000 | – | 400,000 | +100.0% | 0.57% | – | |
| MGNX | MACROGENICS INC | $8,402,931 | -12.9% | 1,803,204 | 0.0% | 0.56% | -3.1% | |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $7,227,050 | – | 292,002 | +100.0% | 0.48% | – |
| REPL | REPLIMUNE GROUP INC | $6,617,498 | -26.3% | 386,762 | 0.0% | 0.44% | -17.9% | |
| NTLA | INTELLIA THERAPEUTICS INC | $6,440,488 | -22.5% | 203,684 | 0.0% | 0.43% | -13.7% | |
| PRTA | PROTHENA CORP PLC | $6,171,175 | -29.3% | 127,900 | 0.0% | 0.41% | -21.5% | |
| THESEUS PHARMACEUTICALS INC | $6,047,642 | -71.2% | 2,248,194 | 0.0% | 0.40% | -67.9% | ||
| ARVN | ARVINAS INC | $5,603,901 | -20.9% | 285,331 | 0.0% | 0.37% | -12.1% | |
| BLUE | BLUEBIRD BIO INC | $5,198,117 | -7.6% | 1,709,907 | 0.0% | 0.34% | +2.7% | |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $4,864,896 | -16.2% | 849,022 | +13.4% | 0.32% | -6.9% |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $4,706,400 | -9.7% | 370,000 | 0.0% | 0.31% | +0.6% | |
| STRO | SUTRO BIOPHARMA INC | $2,706,600 | -25.4% | 780,000 | 0.0% | 0.18% | -17.1% | |
| GRTS | Sell | GRITSTONE BIO INC | $2,461,110 | -47.4% | 1,430,878 | -40.4% | 0.16% | -41.8% |
| ACRS | ACLARIS THERAPEUTICS INC | $1,810,982 | -33.9% | 264,377 | 0.0% | 0.12% | -26.8% | |
| SNDX | New | SYNDAX PHARMACEUTICALS INCput | $1,566,000 | – | 600,000 | +100.0% | 0.10% | – |
| ADCT | ADC THERAPEUTICS SA | $1,477,386 | -58.3% | 1,647,030 | 0.0% | 0.10% | -53.6% | |
| PASG | Sell | PASSAGE BIO INC | $1,156,908 | -33.6% | 1,758,219 | -5.0% | 0.08% | -26.0% |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $950,633 | -9.1% | 500,333 | 0.0% | 0.06% | +1.6% | ||
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -300,000 | -100.0% | -0.34% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -100,430 | -100.0% | -0.61% | – |
| MORF | Exit | MORPHIC HLDG INC | $0 | – | -265,511 | -100.0% | -0.91% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -4,345,559 | -100.0% | -9.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.